Quarterly Results

ALEMBIC PHARMACEUTICALS LTD.

NSE : APLLTDBSE : 533573ISIN CODE : INE901L01018Industry : Pharmaceuticals & DrugsHouse : Alembic
BSE950.8511.8 (+1.26 %)
PREV CLOSE ( ) 939.05
OPEN PRICE ( ) 954.05
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 3683
TODAY'S LOW / HIGH ( )942.25 967.70
52 WK LOW / HIGH ( )536.6 1093.05
NSE958.0017.75 (+1.89 %)
PREV CLOSE( ) 940.25
OPEN PRICE ( ) 940.40
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 958.00 (223)
VOLUME 60861
TODAY'S LOW / HIGH( ) 940.40 972.15
52 WK LOW / HIGH ( )537.75 1094
Quarters
Select year  
( in Million)
Particulars
Dec 2023
Sep 2023
Jun 2023
Mar 2023
Audited / UnAudited
UnAudited
UnAudited
UnAudited
Audited
Net Sales
16305.7
15949.3
14861.5
14064.5
Total Expenditure
13642.1
13866.9
12874.6
11942.3
PBIDT (Excl OI)
2663.6
2082.4
1986.9
2122.2
Other Income
28.9
101.5
116.7
8.9
Operating Profit
2692.5
2183.9
2103.6
2131.1
Interest
151.7
156.9
143.9
143.7
Exceptional Items
NA
NA
NA
NA
PBDT
2540.8
2027
1959.7
1987.4
Depreciation
694.5
675.6
661.8
741.2
Profit Before Tax
1846.3
1351.4
1297.9
1246.2
Tax
41.3
-19.3
91.6
-364.3
Provisions and contingencies
NA
NA
NA
NA
Profit After Tax
1805
1370.7
1206.3
1610.5
Extraordinary Items
NA
NA
NA
NA
Prior Period Expenses
NA
NA
NA
NA
Other Adjustments
NA
NA
NA
NA
Net Profit
1805
1370.7
1206.3
1610.5
Minority Interest
NA
NA
NA
NA
Shares of Associates
-0.5
-5.1
-0.3
-84.5
Other related items
Misc. Expenses Written off
NA
NA
NA
NA
Consolidated Net Profit
1804.5
1365.6
1206
1526
Equity Capital
393.1
393.1
393.1
393.1
Face Value (IN RS)
2
2
2
2
Reserves
NA
NA
NA
NA
Calculated EPS
9.18
6.94
6.13
7.76
Calculated EPS (Annualised)
36.72
27.79
24.54
31.05
No of Public Share Holdings
59734871
59734871
59734871
59734871
% of Public Share Holdings
30.39
30.39
30.39
30.39
 
NA
NA
NA
NA
PBIDTM% (Excl OI)
16.33
13.05
13.36
15.08
PBIDTM%
16.51
13.69
14.15
15.15
PBDTM%
15.58
12.70
13.18
14.13
PBTM%
11.32
8.47
8.73
8.86
PATM%
11.06
8.59
8.11
11.45
 
Notes
Notes
Notes
Notes

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.